Elonva

RSS

corifollitropin alfa

Authorised
This medicine is authorised for use in the European Union.

Overview

Elonva is a hormonal medicine used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries. It is used together with a gonadotrophin-releasing hormone (GnRH) antagonist (another type of medicine used in fertility treatments).

Elonva contains the active substance corifollitropin alfa.

This EPAR was last updated on 26/11/2019

Authorisation details

Product details
Name
Elonva
Agency product number
EMEA/H/C/001106
Active substance
corifollitropin alfa
International non-proprietary name (INN) or common name
corifollitropin alfa
Therapeutic area (MeSH)
  • Reproductive Techniques, Assisted
  • Ovulation Induction
Anatomical therapeutic chemical (ATC) code
G03GA09
Publication details
Marketing-authorisation holder
Merck Sharp Dohme Limited
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
25/01/2010
Contact address
Hertford Road
EN11 9BU Hoddesdon
United Kingdom

Product information

12/09/2019 Elonva - EMEA/H/C/001106 - II/0046

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Controlled ovarian stimulation in combination with a gonadotrophin-releasing-hormone antagonist for the development of multiple follicles in women participating in an assisted-reproductive-technology programme.

Assessment history

How useful was this page?

Add your rating